ACQUISITIONS (Details) $ in Thousands				1 Months Ended	3 Months Ended			6 Months Ended		12 Months Ended
	Nov. 07, 2017 USD ($)	Nov. 17, 2015 USD ($) patent	Apr. 02, 2015 USD ($)	Jan. 31, 2018	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Dec. 31, 2015 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Purchase price consideration
Research and development expenses					$ 2,180	$ 5,614		$ 3,708	$ 10,698
Endo
ACQUISITIONS AND DISPOSITIONS
Number of patents infringed | patent		3
Slan | License Agreement
ACQUISITIONS AND DISPOSITIONS
License agreement term (in years)	10 years
License fee	$ 5,000
Company's marketing and selling term (in years)	7 years
Slan's selling term after the Company's (in years)	3 years
Purchase price consideration
Research and development expenses	$ 24,900
Cebranopadol
ACQUISITIONS AND DISPOSITIONS
Period of time written notice of termination (in days)				120 days
Purchase price consideration
Cash Paid		$ 25,000
Contingent consideration payable		0
Research and development expenses		54,900
Cebranopadol | Endo
Purchase price consideration
Non-cash adjustment		29,900
Cebranopadol | Endo | Non-cash gain on settlement agreement
Purchase price consideration
Non-cash adjustment		$ 29,900
NUCYNTA
Purchase price consideration
Cash Paid			$ 1,050,000
Rebates Payable By Seller			9,977
Total Purchase Consideration			1,040,023
Amount of decrease in the rebate payment							$ 500
Amount of rebate payable estimated on the acquisition date			10,500
Increase in the purchase consideration and fair value of NUCYNTA U.S product rights							$ 500
Fair values of tangible and identifiable intangible assets acquired and liabilities assumed
Intangible asset - acquired entity product rights			1,019,978
Inventories			11,590
Property, plant and equipment			8,455
Total			$ 1,040,023
Other information
Estimated useful life of intangible asset			10 years
Business acquisition step up in value of inventories			$ 5,900
NUCYNTA | Selling general and administrative expense
Fair values of tangible and identifiable intangible assets acquired and liabilities assumed
Non-recurring transaction costs											$ 12,300
Lazanda
ACQUISITIONS AND DISPOSITIONS
Gain on divestiture										$ 17,100